Association of clinicopathological features among tumours of BRCA1 families, BRCA2 families and non-BRCA1/BRCA2 families compared with tumours from patients with sporadic breast cancer


BRCA1 cases
BRCA2 cases
Non-BRCA1/BRCA2
Sporadic



n
%
P
n
%
P
n
%
P
n
%

All
46


40


358


364

Oestrogen receptor
     Negative
33
75.0
<0.0005
15
38.5
0.013
79
24.3
0.294
75
20.9
     Positive
11
25.0

24
61.5

246
75.7

283
79.1
Progesterone receptor
     Negative
37
84.1
<0.0005
21
53.8
0.014
115
35.6
0.657
122
34.0
     Positive
7
15.9

18
46.2

208
64.4

237
66.0
Grade
     I
1
2.2
<0.0005
8
20.0
0.933
82
23.5
0.717
81
22.3
     II
11
24.4

17
42.5

154
44.1

154
42.4
     III
33
73.3

15
37.5

113
32.4

128
35.3
T
     1
21
46.7
0.079
18
54.5
0.516
229
65.6
0.144
219
60.3
     2 to 4
24
53.3

15
45.5

120
34.4

144
39.7
N
     0
32
71.1
0.026
15
44.1
0.289
214
61.1
0.043
193
53.6
     1
13
28.9

19
55.9

136
38.9

167
46.4
M
     0
41
93.2
0.570
28
90.3
0.245
338
98.8
0.005
335
95.2
     1
3
6.8

3
9.7

4
1.2

17
4.8
p53
     Negative
25
62.5
0.017
26
76.5
0.707
261
76.5
0.399
267
79.2
     Positive
15
37.5

8
23.5

80
23.5

70
20.8
HER2
     Negative
30
100
0.017
27
100
0.023
256
85.3
0.598
269
83.8
     Positive
0
0

0
0

44
14.7

52
16.2
CK-5/6
     Negative
28
82.4
0.250
24
92.3
0.599
289
86.8
0.383
299
89.0
     Positive
6
17.6

2
7.7

44
13.2

37
11.0
CK-14
     Negative
20
60.6
<0.0005
19
73.1
0.011
257
79.3
<0.0005
294
89.6
     Positive
13
39.4

7
26.9

67
20.7

34
10.4
CK-17
     Negative
42
97.7
0.866
34
100
0.326
309
96.6
0.624
316
97.2
     Positive
1
2.3

0
0

11
3.4

9
2.8
Age (years)
     ≥50
16
34.8
<0.0005
22
55.0
0.004
215
60.1
0.035
246
67.6
     <50
30
65.2

18
45.0

143
39.9

118
32.4

CK, cytokeratin; HER2, human epidermal growth factor receptor 2.

From Eerola et al. Breast Cancer Research 2008 10:R17   doi:10.1186/bcr1863



Return to top of this page



Return to Genetics page